Recruiting

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab, Drug: carboplatin, Drug: paclitaxel, Other: questionnaire administration, Other: study of socioeconomic and demographic variables, Procedure: quality-of-life assessment
Phase: Phase III

Recruiting

Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Malignant Tumor of Peritoneum
Interventions: Biological: bevacizumab, Drug: carboplatin, Drug: docetaxel, Drug: paclitaxel
Phase: Phase III

Recruiting

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab, Drug: carboplatin, Drug: cisplatin, Drug: paclitaxel
Phase: Phase III

Recruiting

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
Conditions: Ovarian Cancer
Interventions: Drug: bevacizumab [Avastin], Drug: paclitaxel, Drug: topotecan, Drug: liposomal doxorubicin
Phase: Phase III

Recruiting

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer, Ovarian Cancer
Interventions: Biological: bevacizumab, Drug: capecitabine, Drug: carboplatin, Drug: oxaliplatin, Drug: paclitaxel, Procedure: quality-of-life assessment
Phase: Phase III

Recruiting

TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Interventions: Drug: AMG 386, Drug: AMG 386 Placebo
Phase: Phase III

Recruiting

A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer
Conditions: Ovarian Cancer
Interventions: Drug: bevacizumab [Avastin], Drug: carboplatin, Drug: Paclitaxel
Phase: Phase III

Recruiting

Evaluation of Optimal Initial Treatment Duration of Bevacizumab in Combination With Standard Chemotherapy in Patients With Ovarian Cancer
Conditions: Genital Diseases, Female, Ovarian Diseases, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
Interventions: Biological: Bevacizumab, Biological: Bevacizumab, Drug: Paclitaxel, Drug: Carboplatin, Other: specialized pathology review (Germany only)
Phase: Phase III

Recruiting

TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
Interventions: Drug: AMG 386, Drug: Paclitaxel, Drug: AMG 386 Placebo, Drug: Carboplatin
Phase: Phase III

Recruiting

Carboplatin With or Without Thalidomide in Treating Patients With Ovarian Epithelial Cancer
Conditions: Ovarian Cancer
Interventions: Drug: carboplatin, Drug: thalidomide
Phase: Phase II

Recruiting

Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer
Conditions: Peritoneal Cancer
Interventions: Drug: Sorafenib, Biological: Bevacizumab, Genetic: proteomic profiling, Other: laboratory biomarker analysis, Procedure: dynamic contract-enhanced magnetic resonance imaging, Procedure: needle biopsy, Procedure: positron emission tomography, Radiation: fludeoxyglucose F 18
Phase: Phase II

Recruiting

Bevacizumab and Carboplatin for Patients With Ovarian Cancer
Conditions: Ovarian Cancer
Interventions: Drug: Bevacizumab, Drug: Carboplatin
Phase: Phase II

Recruiting

Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab, Drug: everolimus, Other: placebo
Phase: Phase II

Recruiting

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
Conditions: Solid Tumors, Cancer
Interventions: Drug: XL184, Drug: Placebo, Drug: XL184, Drug: XL184
Phase: Phase II

Recruiting

Temsirolimus and Bevacizumab in Treating Patients With Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Liver Cancer, Islet Cell Cancer, or Carcinoid Tumor
Conditions: Endometrial Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Liver Cancer, Lung Cancer, Ovarian Cancer
Interventions: Biological: bevacizumab, Drug: temsirolimus, Other: laboratory biomarker analysis
Phase: Phase II

Recruiting

Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer
Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: Drug: RAD001, Drug: bevacizumab
Phase: Phase II

Recruiting

AMG 102 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Malignant Tumor of Peritoneum
Interventions: Biological: rilotumumab, Other: laboratory biomarker analysis
Phase: Phase II

Recruiting

Efficacy and Safety Study of Sorafenib With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer
Conditions: Ovarian Cancer
Interventions: Drug: Sorafenib
Phase: Phase II

Recruiting

Irinotecan and Bevacizumab for Recurrent Ovarian Cancer
Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions: Drug: Irinotecan and Bevacizumab
Phase: Phase II

Recruiting

First-line Treatment of Weekly Paclitaxel With Carboplatin and Bevacizumab in Ovarian Cancer
Conditions: Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Bevacizumab
Phase: Phase II

Recruiting

Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Conditions: Fallopian Tube Neoplasms, Ovarian Cancer, Primary Peritoneal
Interventions: Drug: Gemcitabine/Bevacizumab
Phase: Phase II

Recruiting

Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Clear Cell Ovarian Cancer
Conditions: Ovarian Cancer
Interventions: Drug: carboplatin, Drug: paclitaxel, Drug: temsirolimus, Other: laboratory biomarker analysis
Phase: Phase II

Recruiting

Clinical Trial Investigating Pazopanib in Patients With Platinum-resistant Advanced Ovarian Cancer
Conditions: Platinum-resistant Advanced Ovarian Cancer
Interventions: Drug: Pazopanib
Phase: Phase II

Recruiting

MK-2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer
Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: Drug: MK-2206
Phase: Phase II

Recruiting

Bevacizumab With or Without Fosbretabulin Tromethamine in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab, Drug: fosbretabulin tromethamine
Phase: Phase II

Recruiting

Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
Conditions: Ovarian Cancer Recurrent
Interventions: Drug: Ombrabulin (AVE8062), Drug: Placebo, Drug: Paclitaxel, Drug: Carboplatin
Phase: Phase II

Recruiting

Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer
Conditions: Ovarian Cancer
Interventions: Drug: NGR-hTNF, Drug: Pegylated liposomal doxorubicin, Drug: Doxorubicin
Phase: Phase II

Recruiting

Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Conditions: Recurrent Ovarian Cancer, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
Interventions: Biological: Chimeric monoclonal antibody (TRC105) to CD105
Phase: Phase II

Recruiting

Activity, Tolerability, Safety of Temsirolimus in Women With Ovarian Cancer Who Progressed During Previous Platinum Chemotherapy or Within 6 Months After Therapy or Advanced Endometrial Carcinoma
Conditions: Genital Diseases, Female, Ovarian Diseases, Ovarian Neoplasms, Endometrial Neoplasms
Interventions: Drug: Temsirolimus
Phase: Phase II

Recruiting

Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel, Drug: pazopanib hydrochloride, Other: placebo
Phase: Phase II

Recruiting

EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: Biological: EGEN-001, Other: laboratory biomarker analysis
Phase: Phase II